PROOF-HD

Resultados de la pridopidina sobre la funcionalidad en la enfermedad de Huntington

Completado

Novedades:

El nuevo artículo de HDBuzz «Los científicos identifican con precisión cómo funciona la pridopidina en modelos de la enfermedad de Huntington» de la Dra. Rachel Harding trae noticias emocionantes sobre el estudio potencial PROOF-HD. Artículo completo aquí
 

MÁS INFO

PATROCINADOR

Prilenia Neurotherapeutics y Huntington Study Group

PARTICIPANTES

480

PROOF-HD es un estudio clínico de fase 3 que evalúa la eficacia y la seguridad de la pridopidina en pacientes con la fase inicial de la enfermedad de Huntington. La pridopidina es una pequeña molécula desarrollada por Prilenia para el tratamiento de trastornos neurodegenerativos como la EH.

Según Prilenia, la Pridopidina es un fármaco oral que se administra en una pequeña cápsula fácil de tragar dos veces al día, que entra en el cerebro y la médula espinal, donde activa una proteína llamada receptor sigma-1 (S1R). La activación del S1R por la pridopidina mejora la eliminación de las proteínas tóxicas, aumenta la producción de energía y reduce el estrés celular y la inflamación. Estos mecanismos son cruciales para la función y la supervivencia de las neuronas.

Webinar (EN): Todo lo que necesitas
saber sobre PROOF HD

El Dr Michael Hayden presenta la
Fase 3 de PROOF-HD

Edades elegibles
para el estudio:

25 años y más

(adulto, adulto mayor)

Sexos elegibles
para el estudio:

Todos

Acepta voluntarios sanos:

No

Criterios de inclusión:

  1. Diagnóstico de la enfermedad de Huntington (HD) basado en las características clínicas y la presencia de ≥36 repeticiones CAG en el gen de la huntingtina
  2. Nivel de confianza diagnóstica de 4
  3. HD de inicio en la edad adulta con inicio de signos y síntomas ≥18 años de edad
  4. Etapa 1 o Etapa 2 de la HD, definida como una puntuación UHDRS-TFC de ≥7, en el momento de la selección.

Criterios de exclusión:

  1. Uso de pridopidina en los 12 meses anteriores a la visita inicial.
  2. Terapia genética en cualquier momento
  3. Cualquier afección médica grave o anomalía de laboratorio clínicamente significativa o de signos vitales que impida la participación segura del paciente en el estudio y su finalización, por ejemplo, enfermedad cardíaca significativa dentro de las 12 semanas anteriores al inicio del estudio o antecedentes de ciertas arritmias cardíacas.
  4. Antecedentes de epilepsia o convulsiones en los últimos 5 años.
  5. Embarazada o en período de lactancia, o intención de quedar embarazada durante el estudio

PAÍSES

Sitios

Austria

Lugar: Medizinische Universität Innsbruck

Dirección: Innsbruck

Contacto: Dora Valent, Study Site Coordinator

Tel: 0512 504 83237
Email: dora.valent@tirol-kliniken.at

República Checa

Lugar: Centrum extrapyramidových onemocnění

Dirección: Praga

Contacto: Jiri Klempir, MD, Study Site Investigator
Tel:   +420  732 273 271
Email:  Jiri.Klempir@seznam.cz

Francia

Lugar: Centre Hospitalier Universitaire (CHU) Henri Mondor

Dirección: París

Lugar: Centre Hospitalier Universitaire (CHU) Amiens-Picardie

Dirección: Amiens

Lugar:Centre Hospitalier Universitaire (CHU) de Bordeaux

Dirección: Burdeos

Alemania

Lugar: Euregional Huntington Center Aachen (EHZA) 

Dirección: Aquisgrán

Contacto: Maha Sagar, Study Site Coordinator, Email: NeuroStudien@ukaachen.de Tel: +49 241 80 80697

Lugar: George Huntington Institut

Dirección: Münster

Contacto: Tel: +49 251 7887880
Email: info@ghi-muenster.de

Lugar: Huntington Center North Rhine-Westphalia,
Department of Neurology,
Ruhr-University Bochum,
St. Josef-Hospital Bochum

Dirección: Bochum

Contacto: Email: d.kaminski@klinikum-bochum.de
Tel.: +49-234-509-2703

Lugar: Kbo-Isar-Amper-Klinikum Taufkirchen (Vils)

Dirección: Taufkirchen (Vils)

Contacto: Michael Bachmaier, Study Site Coordinator
Email: Michael.Bachmaier@kbo.de
Tel: 08084-934-417

Lugar: University of Lübeck

Dirección: Lubeca

Contacto: Saruhi Surnaschjan, Study Site Coordinator 
Phone:+49 451 50043497
Email: saruhi.surnaschjan@neuro.uni-luebeck.de

Lugar Ulm University

Dirección: Ulm

Italia

Lugar: IRCCS Istituto delle Scienze Neurologiche di Bologna

Dirección: Bolonia

Contacto: Tel: +393387367104
Email: unitastudiclinici@ausl.bologna.it

Lugar: Fondazione IRCCS Istituto Neurologico Carlo Besta

Dirección: Milán

Contacto: Tel: +39 02 23942519
Email: centroHD@istituto-besta.it

Lugar: CSS-Mendel Institute at IRCCS Casa Sollievo della Sofferenza Research Hospital

Dirección: Roma

Contacto: Tel: +39 06 44700887
Email: info@lirh.it

Países Bajos

Lugar: Maastricht University

Dirección: Maastricht 

Contacto: Dr. Mayke Oosterloo, Study Site Investigator
Tel: 0031-(0)43-387 76 76, Email: expertisecentrumhuntington@mumc.nl

Lugar: Leiden University Medical Center

Dirección: Leiden

Contacto: Tel: 0031715265442 
Email: huntington@lumc.nl

Polonia

Lugar: Szpital Specjalistyczny Swietego Wojciecha

Dirección: Gdansk

Contacto: Agnieszka Konkel, Study Site Coordinator
Tel: +48 609 952 555
Email: konkel1989@gmail.com

Lugar:Instytut Psychiatrii i Neurologii

Dirección: Varsovia

Contacto: Grzegorz Witkowski, Study Site Investigator
Email: gwitkowski@ipin.edu.pl
Phone: +48694904208

Lugar: Krakowska Akademia Neurologii

Dirección: Cracovia

Contacto: Email: centrum@neurologia.org.pl 
Tel: +48 12 426 92 80

España

Lugar: Hospital de la Santa Creu i Sant Pau

Dirección: Barcelona

Contacto: Dr. Jaime Kulisevsky
Email: JKulisevsky@santpau.cat
Tel: +34 649 14 23 60

Lugar: Fundacion Hospital Universitario La Fé

Dirección: Valencia

Contacto: Francisco Castera, Study Site Coordinator
Email: franciscocasteraenroll@gmail.com

Carmen PEIRO, Study Site Investigator

Email: cpeirov@gmail.com
Tel: Phone: +34 682893185

Lugar: Burgos Foundation for Health Research

Dirección: Burgos

Contacto: Tel:  +34 947 28 18 00 ext 35380
Email: jessicajrp@hubu.es

mcubo@saludcastillayleon.es

Lugar: Hospital Ramón y Cajal

Dirección: Madrid

Contacto: Email: joselopezsendon@hotmail.com
Tel: +34  638 158 849

Reina Unido

Lugar: University of Aberdeen, Institute of Medical Sciences

Dirección: Aberdeen (Scotland)

Contacto: Stella Sihlabela, Study Site Coordinator
Tel: +44 1224 552120
Email: stella.sihlabela@nhs.scot

Resifina Seyara, Study Site Coordinator
Tel: +44 1224 552120
Email: resifina.seyara@nhs.scot

Lugar: Barberry National Centre for Mental Health

Dirección: Birmingham (England)

Lugar: Cardiff University

Dirección: Cardiff (Wales)

new FB feed (19)

dictionary:

SNP-single nucleotide polymorphisms

a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.

 
new FB feed (19)

dictionary:

at risk

You do not know if you carry the genetic mutation for HD gene 

 
new FB feed (19)

dictionary:

TFC-total functional capacity

A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity. 

 
new FB feed (19)

dictionary:

Double-blinded

 means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.

new FB feed (19)

dictionary:

Open label

A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.

new FB feed (19)

dictionary:

Gene therapy

a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.

new FB feed (19)

dictionary:

UHDRS- Unified Huntington Disease Rating Scale

A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD

new FB feed (19)

dictionary:

CAG repeat

The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD

new FB feed (19)

dictionary:

Wild-type

the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein

new FB feed (19)

dictionary:

Tolerabilty

How well a person can handle a treatment without having serious or uncomfortable side effects.

new FB feed (19)

dictionary:

Striatum

Part of the brain that  coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.

new FB feed (19)

dictionary:

Randomized allocation

A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

new FB feed (19)

dictionary:

Radioligand

a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity

new FB feed (19)

dictionary:

Protein

Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.

new FB feed (19)

dictionary:

Premanifest / Prodromal

Prior to onset or diagnosis of movement symptoms.

new FB feed (19)

dictionary:

Placebo

A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.

new FB feed (19)

dictionary:

PK - Pharmacokinetics

The movement of drugs through the body

new FB feed (19)

dictionary:

PD - Pharmacodynamics

The body’s biological response to drugs

new FB feed (19)

dictionary:

PET scan

Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.

new FB feed (19)

dictionary:

Neuron

Brain cells that store and transmit information

new FB feed (19)

dictionary:

MRI

Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones 

new FB feed (19)

dictionary:

mHTT

Mutant huntingtin protein. The protein produced by the faulty HD gene.

new FB feed (19)

dictionary:

Manifest

after HD diagnosis, or when symptoms are already showing

new FB feed (19)

dictionary:

Longitudinal study

A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once

new FB feed (19)

dictionary:

HTT

one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15

new FB feed (19)

dictionary:

fMRI

functional MRI:As with MRI, a technique using powerful magnetic fields  but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes

new FB feed (19)

dictionary:

CSF - cerebrospinal fluid

A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.

new FB feed (19)

dictionary:

Efficacy

A measure of whether a treatment works or not

new FB feed (19)

dictionary:

ASO(Antisense oligonucleotides)

A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene

new FB feed (19)

dictionary:

Biomarker

a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable

new FB feed (19)

dictionary:

BDNF

Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.

new FB feed (19)

dictionary:

Allele

one of the two copies of a gene

new FB feed (19)

dictionary:

Plasma

Liquid component of the blood.

new FB feed (19)

dictionary:

Gene

The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.

new FB feed (19)

dictionary:

Phase

Clinical trial phases are different stages of research that assess the safety and effectiveness of a new medical treatment or intervention in humans.

Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring.